CD24 interacts with EDN1 to activate NFκB signaling driving triple-negative breast cancer tumor progression and paclitaxel resistance
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2027
DOI: 10.1016/j.bbadis.2026.168455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2027. Verfasst von YingCheng Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Hunan Traditional Chinese Medical College, 412012, Zhuzhou, Hunan, China. Hauptthemen laut MEDLINE: Paclitaxel, CD24 Antigen, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Breast cancer (BC) is the most common malignant tumor among women worldwide, and its chemotherapy resistance poses a major challenge in clinical treatment. Triple-negative breast cancer (TNBC) is a specific type of breast cancer that has attracted significant attention due to its extremely poor prognosis. The effectiveness of treatment and the prognosis for survival are significantly impacted by paclitaxel (PTX) resistance, a key chemotherapy medication for BC patients, particularly those with TNBC. CD24 is considerably overexpressed in PTX-resistant MDA-MB-231 cells and tissues, and it is directly linked to a bad prognosis for patients, according to this study's bioinformatics analysis and experimental confirmation. According to mechanistic research, CD24 suppresses MDA-MB-231 cell apoptosis while increasing invasion and proliferation by directly interacting with Endothelin-1 (EDN1) to activate the NFκB signaling pathway. Experiments both in vitro and in vivo demonstrate that CD24 knockdown dramatically reduces tumor development and increases PTX sensitivity. The CD24-EDN1-NFκB axis has a crucial role in PTX resistance in TNBC, according to this study, offering a new therapeutic target for treating chemotherapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Hunan Traditional Chinese Medical College, 412012, Zhuzhou, Hunan, China.
- Department of hepatobiliary surgery, The Third People's Hospital of Yong zhou, 425000, Yong zhou, Hunan, China.
- Department of Internal Medicine, Hunan Traditional Chinese Medical College, 412012, Zhuzhou, Hunan, China.
- Department of Anesthesiology, the Second Affiliated Hospital, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, China.
- Department of Breast and Thyroid Surgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, China. Electronic address: 2004020011@usc.edu.cn.
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Deng, Y., Tian, J., Zhang, L., Luo, J., & Cao, H. (2027). CD24 interacts with EDN1 to activate NFκB signaling driving triple-negative breast cancer tumor progression and paclitaxel resistance. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2026.168455
Vancouver
Deng Y, Tian J, Zhang L, Luo J, Cao H. CD24 interacts with EDN1 to activate NFκB signaling driving triple-negative breast cancer tumor progression and paclitaxel resistance. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2027. doi:10.1016/j.bbadis.2026.168455
BibTeX
@article{Deng2027,
author = {Deng, YingCheng and Tian, JunJie and Zhang, LiJun and Luo, Jie and Cao, Hong},
title = {CD24 interacts with EDN1 to activate NFκB signaling driving triple-negative breast cancer tumor progression and paclitaxel resistance},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2027},
doi = {10.1016/j.bbadis.2026.168455}
}
EUVIMED